J A M Vos1, T Wieldraaijer2, H C P M van Weert2, K M van Asselt2. 1. Department of General Practice, Amsterdam UMC, University of Amsterdam, Post-box 22660, 1100 DD, Amsterdam, the Netherlands. j.a.m.vos@amsterdamumc.nl. 2. Department of General Practice, Amsterdam UMC, University of Amsterdam, Post-box 22660, 1100 DD, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Cancer survivorship care is traditionally performed in secondary care. Primary care is often involved in cancer management and could therefore play a more prominent role. PURPOSE: To assess outcomes of cancer survivorship care in primary versus secondary care. METHODS: A systematic search of MEDLINE and EMBASE was performed. All original studies on cancer survivorship care in primary versus secondary care were included. A narrative synthesis was used for three distinctive outcomes: (1) clinical, (2) patient-reported, and (3) costs. RESULTS: Sixteen studies were included: 7 randomized trials and 9 observational studies. Meta-analyses were not feasible due to heterogeneity. Most studies reported on solid tumors, like breast (N = 7) and colorectal cancers (N = 3). Clinical outcomes were reported by 10 studies, patient-reported by 11, and costs by 4. No important differences were found on clinical and patient-reported outcomes when comparing primary- with secondary-based care. Some differences were seen relating to the content and quality of survivorship care, such as guideline adherence and follow-up tests, but there was no favorite strategy. Survivorship care in primary care was associated with lower societal costs. CONCLUSIONS: Overall, cancer survivorship care in primary care had similar effects on clinical and patient-reported outcomes compared with secondary care, while resulting in lower costs. IMPLICATIONS FOR CANCER SURVIVORS: Survivorship care in primary care seems feasible. However, since the design and outcomes of studies differed, conclusive evidence for the equivalence of survivorship care in primary care is still lacking. Ongoing studies will help provide better insights.
BACKGROUND:Cancer survivorship care is traditionally performed in secondary care. Primary care is often involved in cancer management and could therefore play a more prominent role. PURPOSE: To assess outcomes of cancer survivorship care in primary versus secondary care. METHODS: A systematic search of MEDLINE and EMBASE was performed. All original studies on cancer survivorship care in primary versus secondary care were included. A narrative synthesis was used for three distinctive outcomes: (1) clinical, (2) patient-reported, and (3) costs. RESULTS: Sixteen studies were included: 7 randomized trials and 9 observational studies. Meta-analyses were not feasible due to heterogeneity. Most studies reported on solid tumors, like breast (N = 7) and colorectal cancers (N = 3). Clinical outcomes were reported by 10 studies, patient-reported by 11, and costs by 4. No important differences were found on clinical and patient-reported outcomes when comparing primary- with secondary-based care. Some differences were seen relating to the content and quality of survivorship care, such as guideline adherence and follow-up tests, but there was no favorite strategy. Survivorship care in primary care was associated with lower societal costs. CONCLUSIONS: Overall, cancer survivorship care in primary care had similar effects on clinical and patient-reported outcomes compared with secondary care, while resulting in lower costs. IMPLICATIONS FOR CANCER SURVIVORS: Survivorship care in primary care seems feasible. However, since the design and outcomes of studies differed, conclusive evidence for the equivalence of survivorship care in primary care is still lacking. Ongoing studies will help provide better insights.
Entities:
Keywords:
Cancer survivorship care; Primary care; Secondary care; Systematic review
Authors: Greg Rubin; Annette Berendsen; S Michael Crawford; Rachel Dommett; Craig Earle; Jon Emery; Tom Fahey; Luigi Grassi; Eva Grunfeld; Sumit Gupta; Willie Hamilton; Sara Hiom; David Hunter; Georgios Lyratzopoulos; Una Macleod; Robert Mason; Geoffrey Mitchell; Richard D Neal; Michael Peake; Martin Roland; Bohumil Seifert; Jeff Sisler; Jonathan Sussman; Stephen Taplin; Peter Vedsted; Teja Voruganti; Fiona Walter; Jane Wardle; Eila Watson; David Weller; Richard Wender; Jeremy Whelan; James Whitlock; Clare Wilkinson; Niek de Wit; Camilla Zimmermann Journal: Lancet Oncol Date: 2015-09 Impact factor: 41.316
Authors: Ruth A Lewis; Richard D Neal; Nefyn H Williams; Barbara France; Maggie Hendry; Daphne Russell; Dyfrig A Hughes; Ian Russell; Nicholas S A Stuart; David Weller; Clare Wilkinson Journal: Br J Gen Pract Date: 2009-07 Impact factor: 5.386
Authors: E Grunfeld; A Gray; D Mant; P Yudkin; R Adewuyi-Dalton; D Coyle; D Cole; J Stewart; R Fitzpatrick; M Vessey Journal: Br J Cancer Date: 1999-03 Impact factor: 7.640
Authors: Laura A M Duineveld; Hanneke Molthof; Thijs Wieldraaijer; Anthony W H van de Ven; Wim B Busschers; Henk C P M van Weert; Jan Wind Journal: Fam Pract Date: 2019-11-18 Impact factor: 2.267
Authors: Fiona Crawford-Williams; Bogda Koczwara; Raymond J Chan; Janette Vardy; Karolina Lisy; Julia Morris; Mahesh Iddawela; Gillian Mackay; Michael Jefford Journal: Support Care Cancer Date: 2022-01-15 Impact factor: 3.603
Authors: Raymond J Chan; Oluwaseyifunmi Andi Agbejule; Patsy M Yates; Jon Emery; Michael Jefford; Bogda Koczwara; Nicolas H Hart; Megan Crichton; Larissa Nekhlyudov Journal: J Cancer Surviv Date: 2021-03-24 Impact factor: 4.062
Authors: M Provencio; N Romero; J Tabernero; R Vera; D V Baz; A Arraiza; C Camps; E Felip; P Garrido; B Gaspar; M Llombart; A López; I Magallón; V M Ibáñez; J M Olmos; C Mur; A Navarro-Ruiz; A Pastor; M Peiró; J Polo; Á Rodríguez-Lescure Journal: Clin Transl Oncol Date: 2021-10-29 Impact factor: 3.405
Authors: Michael Jefford; Doris Howell; Qiuping Li; Karolina Lisy; Jane Maher; Catherine M Alfano; Meg Rynderman; Jon Emery Journal: Lancet Date: 2022-04-16 Impact factor: 202.731
Authors: Julien A M Vos; Laura A M Duineveld; Vera E van Miltenburg; Inge Henselmans; Henk C P M van Weert; Kristel M van Asselt Journal: Support Care Cancer Date: 2022-06-21 Impact factor: 3.359